Neumora Therapeutics president sells $13,477 in stock

In a recent transaction, Joshua Pinto, President of Neumora Therapeutics , Inc. (NASDAQ:NMRA), sold 8,048 shares of the company’s common stock. The sale, executed on February 18, 2025, was completed at an average price of $1.6746 per share, resulting in a total transaction value of $13,477. The transaction occurs as NMRA trades near its 52-week low of $1.60, significantly down from its high of $21.00. According to InvestingPro analysis, the stock currently shows signs of being oversold.

This transaction was conducted under Pinto’s Rule 10b5-1 trading plan, which was initially adopted in April 2024 and amended in May 2024. The plan allows for the automatic sale of shares to cover tax withholding obligations associated with vesting restricted stock units. Despite recent market volatility, InvestingPro data shows the company maintains a strong financial position with a current ratio of 10.98, indicating robust liquidity. Analysts maintain price targets ranging from $4 to $30, suggesting potential upside from current levels.

Following this sale, Pinto holds 76,952 shares directly. Additionally, he holds 138,965 shares indirectly through Maple DE Holdings LLC. The indirect ownership is noted in the filing, with details available upon request. For deeper insights into insider trading patterns and comprehensive financial analysis, including 13 additional ProTips, check out the full company report on InvestingPro.

In other recent news, Neumora Therapeutics has undergone significant leadership changes, with co-founder Paul L. Berns stepping in as CEO and chairman of the Board. The company is preparing to release its fourth quarter and full-year 2024 financial results in March 2025. Meanwhile, Neumora’s lead drug candidate, navacaprant, faced a setback after failing a crucial Phase 3 trial for major depressive disorder (MDD), resulting in a significant drop in the company’s stock price. Despite this, BofA Securities maintained a Buy rating on Neumora, albeit with a reduced price target of $7.00, down from $22.00, citing optimism for ongoing trials.

H.C. Wainwright also reiterated its Buy rating, with a price target of $30.00, expressing confidence in the drug’s mechanism, particularly noting positive results among female patients. Mizuho (NYSE:MFG) Securities echoed a positive outlook by maintaining an Outperform rating and a $20.00 price target, looking forward to updates from Neumora on its navacaprant program. In contrast, RBC Capital Markets downgraded Neumora to Sector Perform, lowering the price target to $4.00 due to concerns over the trial’s failure. These recent developments reflect a mix of cautious optimism and skepticism among analysts regarding Neumora’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.